- Drug Pipelines
- July 2018
- 616 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- October 2022
- 182 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- October 2022
- 145 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- October 2022
- 140 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- July 2022
- 714 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Drug Pipelines
- November 2019
- 58 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- February 2024
- 140 Pages
Global
From €5302EUR$5,499USD£4,534GBP
- Report
- April 2023
- 147 Pages
Global
From €5784EUR$5,999USD£4,946GBP
- Report
- April 2023
- 160 Pages
Global
From €5784EUR$5,999USD£4,946GBP
- Report
- May 2023
- 160 Pages
Global
From €5784EUR$5,999USD£4,946GBP
Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more